Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotrimazole + hydrocortisone acetate is a topical combination drug containing clotrimazole, an imidazole-class antifungal agent, and hydrocortisone acetate, a mild corticosteroid. Clotrimazole works by inhibiting lanosterol 14α-demethylase, which disrupts fungal cell membrane ergosterol biosynthesis, while hydrocortisone acetate targets glucocorticoid receptors to reduce inflammation, swelling, redness, and itching. This combination is primarily used to treat inflamed fungal skin infections, such as athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), and tinea versicolor. Skinvisible is developing a proprietary formulation of clotrimazole 1% and hydrocortisone acetate 0.5% using its Invisicare polymer technology, which is designed to enhance topical delivery, provide sustained release, and improve skin adherence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole + hydrocortisone acetate.